Seastar Medical Holding Corp. (ICU) - 10-Q Summary
Business Context and Reporting Period
Company: Seastar Medical Holding Corp.
Reporting Period: Quarter and six months ended June 30, 2026.
Business Overview: A commercial-stage healthcare company developing Selective Cytopheretic Device (SCD) technology to modulate inflammation. The company commercializes QUELIMMUNE, an FDA-approved pediatric SCD therapy for acute kidney injury (AKI) due to sepsis (approved Feb 2024). It is currently conducting a pivotal clinical trial (NEUTRALIZE-AKI) for adult AKI patients and holds six Breakthrough Device Designations (BDD) for various indications including cardiorenal syndrome and end-stage renal disease.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2026 |
6 Months Ended June 30, 2026 |
6 Months Ended June 30, 2025 |
|---|---|---|---|
| Net Revenue | $615 | $1,110 | $631 |
| Gross Profit | $561 | $1,010 | $604 |
| Gross Margin | 91.2% | 91.0% | 95.7% |
| Operating Expenses | $4,352 | $8,404 | $6,184 |
| Net Loss | $(3,730) | $(7,251) | $(5,774) |
| Cash and Equivalents (Balance Sheet) | $6,959 (as of June 30, 2026) | ||
| Accumulated Deficit | $(158,965) (as of June 30, 2026) | ||
| Notes Payable | $134 (as of June 30, 2026) |
Cash Flow (Six Months Ended June 30, 2026):
- Net cash used in operating activities: $(5,755) thousand.
- Net cash provided by financing activities: $734 thousand (primarily from equity issuances).
- Net decrease in cash: $(5,021) thousand.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 82% quarter-over-quarter (Q2 2026 vs. Q2 2025) and 76% year-over-year (6 months 2026 vs. 6 months 2025), driven by increased adoption of QUELIMMUNE.
- Expense Increases: Operating expenses rose significantly. R&D expenses increased 143% QoQ and 40% YoY (6 months), driven by higher payroll (reinstatement of bonus plans) and clinical trial costs for the NEUTRALIZE-AKI study. G&A expenses increased 78% QoQ and 30% YoY (6 months), largely due to legal fees related to litigation and director fees.
- Net Loss Expansion: Net loss widened to $3.73 million for Q2 2026 from $2.00 million in Q2 2025, and $7.25 million for the six months ended June 30, 2026, compared to $5.77 million in the prior year period.
- Capital Structure: The company completed a 1-for-10 reverse stock split in January 2026 (combined 1-for-250 with 2024 split). Outstanding common shares increased to 4.26 million as of June 30, 2026.
Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. With $7.0 million in cash and a burn rate of approximately $5.8 million over six months, the company does not believe current cash is sufficient to fund operations for the next 12 months without additional financing.
- Liquidity Strategy: The company relies on equity sales via its Standby Equity Purchase Agreement (SEPA) with Lincoln Park Capital (approx. $13.8 million capacity remaining) and At-The-Market (ATM) offerings (currently restricted by "baby shelf" limitations). It also has a shelf registration with $55.9 million remaining capacity.
- Clinical Milestones: The company anticipates reporting topline results for the NEUTRALIZE-AKI pivotal trial and submitting a Pre-market Approval (PMA) application in 2027, assuming successful outcomes.
- Legal Proceedings: A putative class action lawsuit regarding financial restatements was dismissed with prejudice in April 2026. A related derivative action was dismissed without prejudice in May 2026.
- Nasdaq Compliance: As of July 1, 2026, the company is no longer subject to a Mandatory Panel Monitor regarding minimum stockholders' equity requirements, having maintained compliance.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $7.0 million cash balance against the current burn rate and the timeline for the next equity raise.
- SEPA Utilization: Monitor the utilization of the $13.8 million remaining capacity under the Standby Equity Purchase Agreement as a primary liquidity source.
- NEUTRALIZE-AKI Trial: Track enrollment and safety data for the pivotal adult AKI trial, which is critical for future revenue expansion beyond the pediatric HDE market.
- Revenue Sustainability: Assess the growth trajectory of QUELIMMUNE sales to determine if product revenue can meaningfully offset operating losses before additional dilution is required.
- Legal Exposure: Confirm no new litigation arises following the dismissal of the 2024 class action and derivative suits.